Sarcoidosis is a chronic inflammatory disease with a myriad of clinical manifestations. Treatment involves immunosuppression with corticosteroids or steroid-sparing agents. A proportion of patients does not respond to or are intolerant to therapy. Targeted immunotherapy with biologic agents has emerged as a novel approach with plausible mechanistic reasons to warrant study.
What is known about this subject?
Targeted immunotherapy with biologic agents has emerged as a novel approach, with plausible mechanistic reasons to warrant study in sarcoidosis.
What new information is offered in this review?
Whilst we cannot absolutely conclude that TNF inhibitors are not effective, based upon their impact on lung function, they are unlikely to be the breakthrough therapy that was once envisaged.
What are the implications for research, policy, or practice?
Future research should consider alternative immunomodulatory strategies to treat this disease.
Background
Sarcoidosis is a systemic disease of unknown aetiology that is characterised by granulomatous inflammation which can develop in almost any organ system. The epidemiology of the disease remains poorly defined. Cases are reported worldwide in all races and sexes, although the incidence peaks in young adults and the disease is more frequent in people of black ethnicity. [1] [2] [3] Pulmonary involvement occurs in 90 per cent, with diffuse interstitial disease as the classical presentation. 4 Extra-pulmonary disease is seen in 30 per cent of patients, with cutaneous, ocular, reticuloendothelial, musculoskeletal, cardiac and neurological manifestations. 5 There is no known cure for sarcoidosis. Most patients have asymptomatic non-progressive disease or experience spontaneous remission and thus do not require treatment. For those with more severe disease, treatment is aimed at reducing the burden of granulomatous inflammation and preventing organ damage. 6 Corticosteroids are the mainstay of therapy. In patients who do not respond to, or are intolerant of corticosteroids, a second-line therapeutic agent such as methotrexate or azathioprine is used. [7] [8] [9] [10] [11] The efficacy of current treatment regimens is poor, fostering interest in the use of new medications to treat the disease.
A number of biologic cytokine modulators are used effectively in the management of other inflammatory diseases, particularly inflammatory arthritis. [12] [13] [14] There are plausible mechanistic reasons to warrant study of targeted anti-cytokine therapy in sarcoidosis. Tumour necrosis factor alpha [TNFα] is a key inflammatory cytokine in the immunopathogenesis of sarcoidosis. Its production by monocytes and macrophages plays a pivotal role in the formation and maintenance of non-caseating granulomas. Interleukin [IL]-12 and IL-23 are upregulated in sarcoid lung tissue and skin lesions. 15, 16 Increased IL-6 levels have been reported in bronchoalveolar lavage samples from patients with sarcoidosis 17 and IL-17 has been implicated in granuloma formation. 18 Biological therapies have been reported as being effective in the treatment of refractory organ-threatening sarcoidosis in case reports and small case series. However it is important to recognize that observational reports are limited by small numbers, publication bias and regression to the mean. Furthermore, a lack of validated outcome measures in sarcoidosis and the heterogeneity of the disease further confound these observational findings. This review aims to establish the evidence for the use of biologic agents in the treatment of sarcoidosis.
Method
The study was conducted in accordance with the preferred reporting items for systematic reviews and meta-analysis guidelines. A comprehensive structured literature search was performed using the MEDLINE and Embase database and re-run prior to the final analysis to identify further studies that could be retrieved. The search items were: sarcoid, sarcoidosis, biologics, anti-TNF, infliximab, adalimumab, etanercept, golimumab, certolizumab, rituximab, abatacept, tocilizumab, anakinra, ustekinumab and secukinumab.
English language randomised-controlled trials [RCT] published between 1947 and September 2017 were sought. The reference lists were scrutinised to find additional pertinent trials. Cohort studies, case reports and conference abstracts were excluded. The quality of each trial was assessed using the Jadad score on a scale of 0-5. 19 A metaanalysis was performed evaluating the efficacy of TNFα inhibition in pulmonary sarcoidosis. The change in forced vital capacity [FVC] by weighted mean difference [WMD] was analysed using the available data provided. Analyses were performed using STATA version 14. 
Results

Literature search and study characteristics
The initial search strategy yielded a total of 2,324 articles for screening which was reduced to 6 after application of filters and screening of titles and abstracts. The search strategy is detailed in Figure 1 . In total, 5 studies were original RCTs and eligible for inclusion. These were all randomised, double-blinded, placebo controlled trials, evaluating anti-TNFα inhibition. TNF inhibitors assessed included infliximab, a chimeric monoclonal antibody that blocks TNFα, adalimumab, a fully human monoclonal antibody that blocks TNFα, and etanercept, a recombinant human TNF receptor fusion protein that binds and inactivates TNF. Four studies were two arm trials whilst one study was a threearm trial comparing TNFα, ustekinumab, and placebo. Ustekinumab is a monoclonal antibody that blocks IL-12 and IL-23. There were no RCTs examining other biological therapies.
Five studies were analysed [ Table 1 ]. Of the five studies, two evaluated the efficacy of biological therapy in pulmonary disease, one in cutaneous disease, one in both pulmonary and cutaneous disease and the last in ocular involvement. The primary outcomes were the change in the percentage predicted FVC, the mean change in vital capacity [VC], the reduction in the Physician Global Assessment [PGA] skin score and the improvement in Ophthalmologist Global Assessment score. The number of patients included in the trials ranged from 18 to 173 and the mean age ranged from 46 years to 53 years. 15, [20] [21] [22] [23] The disease duration was reported in only 2 studies, ranging from a mean of 5.6 years to 9.8 years. 21, 23 All included studies scored greater than 3 on the Jadad scale. The key points of each study are summarised in Table 1 .
Key findings
There is limited data on the use of biologic agents in the treatment of sarcoidosis. Only one study demonstrated a significant benefit in treating cutaneous involvement with anti-TNF, with a significant reduction in the PGA score. 23 In pulmonary sarcoidosis, Baughman et al. 21 reported a statistically significant improvement in percentage predicted FVC with infliximab therapy, although no significant differences were observed for any of the major secondary endpoints. The remaining three studies did not report a significant benefit in their primary outcomes in both pulmonary and ocular disease. 15, 20, 22 The two positive
RCTs were either of low quality or limited by small sample sizes. With this current evidence we are unable to conclude that there is a benefit with biological therapy in the treatment of sarcoidosis.
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The second study by Baughman et al. 21 assessed the efficacy of infliximab treatment in pulmonary sarcoidosis. One hundred and thirty-eight patients were enrolled, of which 133 completed the study. This was a three-arm trial in which participants were given placebo, 3mg/kg infliximab or 5mg/kg infliximab at weeks 0, 2, 6, 12, 18 and 24, and then followed up to week 52. 
Meta-analysis of TNF inhibition in pulmonary sarcoidosis
Three studies evaluated the efficacy of TNF therapy in patients with pulmonary sarcoidosis, totalling 270 subjects [161 in TNF arm and 109 in the placebo arm]. Each study reported a different duration until primary outcome; 14 weeks, 28 weeks and 52 weeks. Two of these studies used change in the percentage predicted FVC as the primary outcome. The third study measured mean change in VC. Meta-analysis of change in FVC revealed a statistically significant WMD of 1.69 per cent [95 per cent confidence interval, 1.44-1.94] [ Figure 2 ]. The minimal clinically important difference [MCID] for per cent-predicted FVC lies between 2 per cent and 6 per cent. Thus, although the overall benefit is statistically significant, the result falls below the MCID. 24 There was high heterogeneity between the results from these three trials, despite the entry criteria in the Judson trial 15 matching that of a subgroup in the Baughman trial. 21 
Adverse events
Four out of five studies reported on adverse events. In the infliximab study, Baughman et al. 21 reported serious adverse events in 23 per cent of the infliximab arm and 18 per cent of the placebo arm. Rossman et al. 22 reported serious adverse events in 31 per cent of the infliximab group compared to 17 per cent of the placebo group, with one death in the infliximab group caused by recurrent cellulitis and a pulmonary embolism. Pariser et al. 23 reported one serious adverse event, a pneumonia with adalimumab. Judson et al. 15 reported serious adverse events in 13 per cent and 17 per cent of the golimumab and ustekinumab arms respectively, compared to 16 per cent of the placebo group. Overall the most common event was respiratory tract infections.
Discussion
This systematic review has revealed little evidence to support the use of TNF inhibition in sarcoidosis. One study reported a significant improvement with TNF therapy in cutaneous disease. There was no benefit seen in ocular disease. Of the three studies evaluating chronic pulmonary sarcoidosis, only one reported a significant improvement in its primary endpoint. This improvement was not thought clinically relevant as all other secondary objectives were not met.
Adalimumab was effective in treating cutaneous sarcoidosis. This supports the results from previous studies, albeit not RCTs, which have shown success in therapy-resistant and chronic sarcoidosis. 25 However, the sample size in this study was small [n=16] and as such, a larger scale RCT is required to provide more evidence.
Etanercept therapy did not prove efficacious in the treatment of ocular sarcoidosis. This may be partly explained by the difference in its mechanism of action compared to anti-TNF monoclonal antibody therapy. Etanercept is a soluble form of the p75 TNF receptor and primarily binds only soluble TNF, leaving membranebound TNF partially intact. This may permit maintenance of the granuloma structure. Etanercept is not as effective in treating other granulomatous diseases such as Crohn's, whilst the risk of tuberculosis, an opportunistic granulomatous infection, is lower with etanercept therapy. 26, 27 In pulmonary sarcoidosis, our meta-analysis revealed a statistically significant improvement in FVC with TNF inhibition. However, there was high heterogeneity between the results from the three trials included, and whilst significant, the improvement in FVC fell below the MCID and is likely not clinically relevant. The only study to report a statistically significant benefit in FVC was by Baughman et al. 21 
a 2.5 per cent improvement in percentage predicted
FVC with infliximab. This falls at the lower limit of the MCID, with no improvement in all secondary endpoints. 21 The authors suggest this may relate to the inclusion criteria of stable pulmonary disease on background therapy, which may have diminished the response to infliximab therapy. Post-hoc exploratory analyses of patients with severe disease demonstrated greater improvements in FVC and 6-MWD. 21 Future trials in patients with more extensive lung involvement may be warranted to establish a potential threshold of disease progression after which infliximab is more effective. Rossmann et al. 22 reported a non-significant trend of improvement in VC at six weeks with infliximab. In the open-label extension, the entire cohort received a further two doses and improvement in VC continued, with the authors proposing that a longer duration of treatment may have led to more significant improvements. Judson et al. 15 reported no statistically significant improvement in percentage predicted FVC with golimumab. Sensitivity analysis suggested inefficacy may be related to an inadequate dose. There was greater FVC improvement in patients with higher golimumab trough levels. A trend towards an improved FVC in patients with a body mass index [BMI] less than 30 compared to the group with BMI greater than 30 was also reported.
More research in this area is warranted. The design of future trials evaluating TNF inhibition in sarcoidosis could consider inclusion of patients with more severe disease and ensure longer follow up. However, it is quite possible that if TNF inhibitors were effective in sarcoidosis, we would have observed a benefit. A wiser recommendation may be to direct research to other targeted therapy strategies including IL-17 and IL-6 inhibition or the use of Janus kinase inhibitors or anti-fibrotics. There are currently no RCTs looking at the efficacy of other cytokine blockers. IL-6 is thought to be involved in the initiation and maintenance of alveolitis. Increased levels of IL-6 are reported in bronchoalveolar lavage and have correlated with severity of disease and requirement for steroid therapy. 17, 28 IL-17A has been implicated in granuloma formation with increased IL-17A expression and a greater proportion of circulating TH-17 cells. 18, 29 There is abundant STAT1 expression in lymph node granulomas from patients with active disease, suggesting STAT1 might play an important role, thus, the interference of the JAK-STAT signalling pathway maybe a potential therapeutic target.
Conclusion
The question of whether biological therapy in sarcoidosis is effective cannot be answered with the current evidence. Whilst we cannot absolutely conclude that TNF inhibitors are not effective, based upon their impact on lung function, they are unlikely to be the breakthrough therapy that was once envisaged. Future research should consider alternative immunomodulatory strategies to treat this disease.
